End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25.88 CNY | +0.04% | -2.67% | -37.56% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 60% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company returns high margins, thereby supporting business profitability.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 41.74 times its estimated earnings per share for the ongoing year.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-37.56% | 1.43B | - | ||
+73.63% | 12.42B | B- | ||
-18.62% | 7.94B | C+ | ||
-0.90% | 6.17B | C- | ||
+14.66% | 5.5B | D+ | ||
+39.93% | 5.01B | - | ||
-16.54% | 4.88B | B | ||
-16.42% | 4.2B | B- | ||
-27.62% | 2.73B | C | ||
+40.99% | 2.27B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688161 Stock
- Ratings Shandong Weigao Orthopaedic Device Co., Ltd